- Scancell Holdings said government body Cancer Research UK was planning a clinical trial to to investigate a cancer treatment is was developing jointly with the company.

Cancer Research UK was planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours, the company said.

Scancell and Cancer Research UK are in a clinical development partnership for the development of Scancell's ImmunoBody vaccine, SCIB2, as a potential treatment for patients with solid tumours, including non-small cell lung cancer.

'We are delighted to announce this important milestone in our partnership with Cancer Research UK, which moves us one step closer to entering the clinic,' chief executive Cliff Holloway said.

'This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation.'

'We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally.'

At 9:10am: [LON:SCLP] Scancell Holdings PLC share price was +0.5p at 4.75p

Story provided by